StageZero Life Sciences Ltd
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Majority of Australian Parents (65%) and U.S. Parents 58% Support Social Media Ban for Under 16s, but Kids Say It Risks Cutting Them Off from Key Connections9.12.2025 15:00:00 CET | Press release
New survey of 4,000 parents and children in the U.S. and Australia reveals sharp generational divides in support, fears, mental health expectations, and belief in government enforcement. WASHINGTON, DC / ACCESS Newswire / December 9, 2025 / The Family Online Safety Institute (FOSI) released new research today examining how parents and children in the United States and Australia view social media bans for anyone under 16. The findings reveal strong parental support for such bans, in contrast with widespread concern from children who fear losing friendships and support systems that exist primarily online. The research arrives as Australia implements a national under 16 social media ban, placing global attention on how the policy will affect youth and their families. FOSI's study surveyed 4,000 parents and children ages 10 to 17 to understand how both groups feel about restrictions, enforcement, and the broader impact of social media on daily life. Support for the Ban: Parents vs Children
Techmer PM Joins Formerra's Portfolio in North America9.12.2025 15:00:00 CET | Press release
Formerra will distribute Techmer PM color masterbatches, high-performance additives, and pre-colored compounds across the U.S., Canada, and Mexico. ROMEOVILLE, ILLINOIS / ACCESS Newswire / December 9, 2025 / Formerra, a leader in performance materials distribution, today announced the addition of Techmer PM color masterbatches, high-performance additives, and pre-colored compounds to its expansive portfolio of materials. With this partnership, Formerra advances its application-specific lineup, aligning its material portfolio to customers' evolving needs across North America. A U.S.-based plastics compounder, Techmer PM specializes in value-added color and additive masterbatches and engineered compounds for high-performance plastics and fibers. These products are used in various industries such as medical, automotive, packaging, and consumer goods applications. Techmer PM has consistently invested in its optical and color capabilities, including the recent acquisition of OptiColor Inc.
Cyara Appoints Sushil Kumar as CEO to Extend Enterprise AI Customer Experience (CX) Leadership8.12.2025 22:30:00 CET | Press release
Visionary AI and cloud executive with proven record of building and scaling enterprise platforms to lead the next phase of innovation and global expansion for the CX assurance market leader. AUSTIN, TX / ACCESS Newswire / December 8, 2025 / Cyara, the global leader in AI-powered customer experience (CX) assurance, today announced the appointment of Sushil Kumar as its new Chief Executive Officer. His appointment underscores Cyara's commitment to accelerating enterprise AI CX innovation and elevating customer experience by enabling more reliable, responsive, and trustworthy interactions across every channel. Sushil will build on the strong foundation laid by outgoing CEO Rishi Rana. Sushil brings entrepreneurial vision and enterprise-scale leadership to Cyara. He has focused his career on building category-defining AI, DevOps, and cloud platforms, both as a founder and as a leader of large global organizations. Most recently, he was Co-Founder and CEO of RelicX.ai, a generative AI test
AI21 Labs and Fnac Darty, Partner to Drive Retail AI Transformation8.12.2025 09:00:00 CET | Press release
Fnac Darty selects AI21 as a strategic AI partner to tackle retail's most complex challenges, starting with After-Sales service, with Maestro, the leading AI orchestration platform. PARIS, FR AND TEL AVIV, IL / ACCESS Newswire / December 8, 2025 / AI21 labs, a frontier AI developer and a global leader in enterprise AI, announced a strategic partnership with Fnac Darty, one of Europe's leading retailers with a network of both online and physical stores. The collaboration marks a flagship initiative in Fnac Darty's long-term growth strategy and positions AI21 as a strategic partner for the rollout of AI across the company's operations. The partnership supports Fnac Darty's recently announced "Beyond Everyday" strategic plan, which focuses on accelerating the company's transition from a product-based model to services and subscriptions, with After-Sales at the heart of this evolution. The first use case will focus on after-sales service, a mission-critical area for Fnac Darty and a corner
The 13th GLA Global Logistics Conference Successfully Concludes in Bangkok, Thailand5.12.2025 16:00:00 CET | Press release
More than 2,000 logistics leaders from 130+ countries convene in Thailand to advance peace, digital innovation and trustworthy cooperation in global supply chains. SHENZHEN, CN / ACCESS Newswire / December 5, 2025 / The 13th GLA Global Logistics Conference was successfully held in Bangkok, Thailand from November 7-10, 2025, providing a prestigious international platform for business cooperation in the global logistics sector. Co-organized by the Global Logistics Enterprises Federation (GLEF) and the GLA Global Logistics Alliance, the event centered around the theme "Peaceful Prosperity, Digital Innovation, Trustworthy Cooperation." The conference brought together over 2,000 logistics professionals and industry leaders from more than 130 countries, fostering a unique environment for collaboration and knowledge exchange. With its exceptional industry influence and capacity for cross-border resource integration, GLA continues to emerge as a pivotal force in driving global supply chain inn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom